Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (March 2020)
33 slides from Cocrystal Pharma's investor presentation, Mar 4, 2020
Slide 1: Cocrystal Pharma Investor Presentation March 2020
CO CRYSTAL Investor Presentation PHARMA,INC. March 2020
Slide 2: Forward Looking Statements
uN }@ Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results of our collaboration with Merck Sharp & Dohme Corp. (‘Merck’), including the expected acc
Slide 3: Cocrystal's Seasoned Senior Leadership
Ake Lot Cocrystal’s Seasoned Senior Leadership Manageme! Gary Wilcox, Ph.D. Chairman and Chief Executive Officer + Over 35 years of executive biotech leadership experience and played a key role in the development of Cialis Sam Lee, Ph.D. President + Over 20 years of anti-infective drug discovery res
Slide 4: Corporate Overview
mS ; }@( Corporate Overview ~TF Clinical Stage Antiviral Company Influenza Proprietary Drug Discovery Platform Hepatitis Merck Influenza Collaboration Coronavirus Norovirus Gastroenteritis
Slide 5: Technology and Drug Discovery Platform
Ake Lot Technology and Drug Discovery Platform Technology Platform Based on Nobel Prize-winning technology + Near-atomic resolution + X-ray quality crystal production + Drug pocket selection + Hit-to-lead process + Lead optimization + Drug candidates Drug Discovery Platform Crystal Production Expres
Slide 6: Robust Development Pipeline
Ake Lot Robust Development Pipeline Program Discovery | Pre al| Phase1 Phase2a | Phase2b Phase3 Hepatitisc C-31244— (Pan-genotypic NS5B NNI) (nfuenze EE (Influenza A PB2 Inhibitor) | Infuenzaweinnibitor = > opt Coronavirus Protease Inhibitor hl» Norovirus Noro Polymerase Li! Inhibitor Influenza © ME
Slide 7: Merck/Cocrystal Team Initiates Influenza Collaboration
Ake Lot Merck/Cocrystal Team Initiates Influenza Collaboration Received $4 million upfront payment, eligible to receive up to $156 million in milestone payments and royalties (undisclosed) on product sales Exclusive license and collaboration agreement to discover and develop certain proprietary infl
Slide 8: Kansas State University Research Foundation Agreement
OS Lot Kansas State University Research Foundation Agreement Cocrystal acquires exclusive patent rights and know-how for coronavirus and norovirus therapeutics for humans use « License agreement with Kansas State University Research Foundation (KSURF) to further develop certain proprietary broad-spe
Slide 9: Overview | Antiviral Programs: Hepatitis C
Overview | Antiviral Programs: Hepatitis C
Slide 10: Cocrystal's HCV Strategy
Ake Lot Cocrystal’s HCV Strategy Lead program CC-31244, in ongoing Phase 2a study for the treatment of Hepatitis C Current HCV Market Overview AbbVie’s Mavyret™ Demonstrated Shorter Treatment * Clinical limitations of existing long-term HCV therapies: + Approved broad spectrum HCV combination therap
Slide 11: HCV Is Still a Global Issue
RAS Lol HCV Is Still a Global Issue 71 Million oN) people die annually i 1 people infected globally (a APIS Only 20% Only 2% of infected patients of infected patients have been diagnosed! are being treated’ 1: Polaris Observatory, 2019 11
Slide 12: Hepatitis C Treatment Market Share
Ake Lot Hepatitis C Treatment Market Share 2017 Annual Sales: $12.69 Billion 2018 Annual Sales: $8.3 Billion = Gilead (Harvoni, Epclusa, Sovaldi, Vosevi) ™ Merck (Zepatier) = J&J (Olysio) m AbbVie (Viekira, Mavyret) mAbbVie (Viekira, Mavyret) = Gilead (Harvoni, Epclusa, Sovaldi, Vosevi) = Merck (Zep
Slide 13: CC-31244: Broad Spectrum HCV Non-Nucleoside Inhibitor (NNI)
Akt ; a Lol CC-31244: Broad Spectrum HCV Non-Nucleoside Inhibitor (NNI) Next Generation Combination Therapy HCV GT1—GT6 NS5B Polymerase Crystals + Potential best-in-class HCV NNI with a strong profile : oF « Broad spectrum, potent NSSB polymerase inhibitor ie + High barrier to drug resistance Be, ‘
Slide 14: Potential Best-in-Class NNI
ae }@1 Potential Best-in-Class NNI xT CC-31244 > Genotypes 1-6 > 400 => (3.0) ABT-333 (Dasabuvir)' Genotype 1 400 BID (1.08) 800 BID (0.95) GS-9190 (Tegobuvir) Genotype 1 40 BID (1.0) 120 BID (1.5) 1. Represents approved DAA 14
Slide 15: CC-31244: Phase 2a University of Maryland Study Design
Ake Lot CC-31244: Phase 2a University of Maryland Study Design Open-label, Phase 2a study evaluating the safety, tolerability and preliminary efficacy of CC-31244 with approved HCV DAAs (HCV GT1 subjects, N=12) Sofosbuvir and Follow-Up at Velpatasvir 12 & 24 Weeks @o———- 4 Weeks ——_® CC-31244 (400 m
Slide 16: University of Maryland Phase 2a
Ake Lot University of Maryland Phase 2a Cocrystal Pharma announced safety and preliminary efficacy data for its U.S. Phase 2a study evaluating CC-31244 for the ultra-short treatment of HCV infected individuals: All subjects completed the 6-week treatment regimen The treatment was well tolerated with
Slide 17: Positive Phase 2a Results Demonstrated Ability to Identify Patients
PN }@1 Positive Phase 2a Results Demonstrated Ability to Identify Patients ‘\” More Likely to Respond to Ultrashort Treatment of HCV * 8 of 12 (67%) patients achieved primary endpoint of sustained virologic response (SVR) 12, which is considered a cure * 6 weeks of Epclusa’s therapy combined with on
Slide 18: Overview | Antiviral Programs: Influenza
18 Overview | Antiviral Programs: Influenza
Slide 19: Significant Unmet Need in Growing Influenza Market
Ake Lot Significant Unmet Need in Growing Influenza Market Global influenza market was valued at nearly $5.6 billion in 2017 and is expected to reach nearly $6.5 billion by 2022' Seasonal and pandemic infection 3-5 Million cases of severe illness annually" 1 Billion Up to 650,000 cases annually? dea
Slide 20: Influenza Remains a Major Global Concern
A, ~ SS oe ( Influenza Remains a Major Global Concern Flu season deaths top 80,000 last year, CDC says September27, 2018 US on track for one of TV. the worst flu seasons in decades Jan, 6, 2020 SCIENCE Child Flu Deaths Hit Record High for This Time of Year Jan. 7, 2020 Flu Season Off To Early Start,
Slide 21: Influenza Drug Candidates
Ake Lot Influenza Drug Candidates Influenza A/B Inhibitor Svat? Proprietary Influenza A and B Crystals «3 MERCK Collaboration ¢ Broad spectrum, potent dual influenza A/B preclinical lead will be developed « Result of Cocrystal’s drug discovery platform technology « Binds to highly conserved site of
Slide 22: Influenza Drug Candidates
Ake Lot Influenza Drug Candidates Antiviral Product Candidates Target All Strains of the Influenza A Virus Influenza A Inhibitor Influenza PB2 Lead a Binds to the highly conserved m7GTP binding pocket of PB2 Exhibits broad spectrum activity against seasonal and pandemic influenza strains, EC50 is 0.
Slide 23: Strong Synergistic Effects With Approved Influenza Antivirals
yer c ae tical al Strong Synergistic Effects With Approved ‘«e_ Influenza Antivirals Polymerase Inhibitor Favipiravir t Cocrystal 42344 2+ @~@: PA Inhibitor Neuraminidase Inhibitor
Slide 24: CC-42344: Pharmacological, Safety, Toxicity, and PK Evaluations
CC-42344: Pharmacological, Safety, Toxicity, and PK Evaluations Completed To Date GBECEEEB6BB6B6E66B88 B6BBEB In vitro antiviral profiling against seasonal and pandemic influenza A strains Cytotoxicity including larger screen: HepG2/high content analysis and 13 cell lines Caco-2 bidirectional permea
Slide 25: Overview | Antiviral Programs: Norovirus
25 Overview | Antiviral Programs: Norovirus
Slide 26: Norovirus Is an Area of Significant Unmet Need
uN ( Norovirus Is an Area of Significant Unmet Need Norovirus Market Overview Known Causes of Foodborne Illness Outbreaks, « No approved antiviral drugs for the treatment of Noro infection Parasites 1% Other Norovirus $4.2 billion in direct health system costs’ pas 700 million 19-21 million cheryl i
Slide 27: Cocrystal's Norovirus Program
Ake Lot Cocrystal’s Norovirus Program Norovirus sa NNI Program Noro Polymerase NNIs Norovirus and oraalk Polymerase Crystals Potential first-in-class NNI Potent and broad spectrum Noro polymerase inhibitors Technology platform complete Structure-based lead discovery ongoing
Slide 28: Well-Positioned for Growth
28 Well-Positioned for Growth
Slide 29: Intellectual Property
SS ( Intellectual Property > HCV + NSS5B (non-nucleoside inhibitor) + Issued patents in U.S. + Pending applications in U.S. and worldwide + Pending U.S. provisional application > Influenza + PB2 (influenza A replication inhibitor) + Pending applications in PCT and Taiwan + 3 pending U.S. provisional
Slide 30: Capitalization Table (As of January 31, 2020)
~$65MM 47.1MM ~3.72MM Common shares Average 3 mon 1 Market cap outstanding daily volume? Capitalization Table (As of January 31, 2020) # of Shares | wap | Svaue | % of Fully Diluted Common Shares Outstanding (Directors, Officers and Affiliates) 15,231,113 31.55% Common Shares Outstanding (Other) 31,
Slide 31: Strategy Directed at Advancing Programs and Growing Value
Ake Lot Strategy Directed at Advancing Programs and Growing Value ¢ Growth in focused therapeutic areas * Continue to progress an innovative pipeline * Form additional strategic collaborations and partnerships * Ongoing collaboration with Merck has accelerated influenza A/B development program
Slide 32: Upcoming Milestones Expected to Drive Value
X, Upcoming Milestones Expected to Drive Value Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 H2 2020 Q3 2021 Influenza A Influenza Hepatitis C Influenza A Hepatitis C Coronavirus Norovirus Platform Influenza A Merck AB Hepatitis C Norovirus Commence GLP Toxicology Studies Present Preclinical Data
Slide 33: Thank you!
C¥CRYS TA L Thank you! PHARMA,IN
Cocrystal Pharma — Investor Presentation (March 2020) on 6ix